Ex Parte Langston et al - Page 6



                Appeal No. 2006-0881                                                                                                          
                Application No. 09/928,139                                                                                                    

                Armstrong  because producing higher yields of a desirable single isomer is expected, and such                                 
                expectation is the attributes taught by the prior art” (answer, page 10).                                                     
                         The examiner’s obviousness conclusion is not supported by the here applied prior art.  As                            
                more thoroughly detailed in the supplemental brief and reply brief, none of the secondary                                     
                references applied by the examiner contain any teaching or suggestion of racemizing                                           
                methylphenidate or any similar compound containing two chiral centers and thereby obtaining a                                 
                mixture of all four stereoisomers (as required by the rejected claims) based upon a reasonable                                
                expectation of success.  See In re O’Farrell, 853 F.2d 894, 903-04, 7 USPQ2d 1673, 1681 (Fed.                                 
                Cir. 1988) (obviousness under § 103 requires a reasonable expectation of success).                                            
                         It follows that the § 103 rejection of claims 1-6 and 8 as being unpatentable over Zeitlin                           
                or Armstrong in view of the Miller Chemical Abstracts, the Barry Chemical Abstracts or Miller                                 
                ‘261 cannot be sustained.                                                                                                     
                         In discussing her § 103 rejection of claims 1-8, the examiner has made clear that the                                
                additionally applied Harris reference is relied upon solely for the limitation of dependent claim 7                           
                (see pages 11 and 13 of the answer).  Thus, as applied by the examiner, Harris fails to supply the                            
                above-discussed deficiencies of the other applied references.  For this reason alone, we cannot                               
                sustained the examiner’s § 103 rejection of claims 1-8 as being unpatentable over Zeitlin or                                  
                Armstrong in view of the Miller Chemical Abstracts, the Barry Chemical abstracts or Miller ‘261                               
                in view of Harris.3                                                                                                           


                                                                                                                                             
                3   As an additional matter of concern regarding this rejection, we observe that the examiner has not even attempted          
                to rebut the appellants’ extensive explanation of why the Harris patent should be regarded as disqualified prior art          
                under 35 U.S.C. § 103(c).  It was inappropriate for the examiner and for her appeal conferees to have maintained to           
                this rejection while failing to proffer any rebuttal whatsoever to the appellants’ disqualification argument.                 

                                                                      6                                                                       



Page:  Previous  1  2  3  4  5  6  7  8  Next 

Last modified: November 3, 2007